Clinical trial NCT06142422: Intermittent Theta Burst Stimulation of the Precuneus
Official title: Intermittent Theta Burst Stimulation of the Precuneus for the Treatment of Resistant Schizophrenia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Schizophrenia
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
Collaborators: name: Euraxi Pharma
First posted: 2023-11-21
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: interventional, prospective, randomized, double-blind, multicenter study
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the effectiveness of stimulation of the left precuneus by intermittent Theta Burst Stimulation to placebo stimulation on the severity of schizophrenia symptoms.

Detailed description: This is an interventional, prospective, randomized, double-blind, multicenter study, comparing iTBS treatment (experimental group) of the precuneus to placebo stimulation (control group) of patients suffering from resistant schizophrenia and having been exposed to childhood trauma.

The study population will be patients aged 18 to 40 years old exposed to childhood trauma, presenting with schizophrenia resistant to antipsychotic treatments.

This study will be implemented in 4 investigative centers. Each patient will participate for a period of 3 months.

Eligibility criteria: Inclusion Criteria:

* Right-handed patient aged 18 to 40 years inclusive;
* Patient presenting schizophrenia as defined in the Diagnostic and Statistical Manual-5;
* Patient under antipsychotic treatment in accordance with the recommendations of the High Authority of Health, at a stable dosage and without modification of psychotherapeutic treatment for at least 4 weeks;
* Patient on mono or dual antipsychotic therapy.
* Patient presenting residual symptoms, i.e. absence of remission defined by the criteria of the "Remission criteria of the Schizophrenia Working Group Consensus";
* Patient having been exposed to at least one type of trauma in childhood and having a score higher than the threshold values of the childhood trauma questionnaire: emotional neglect, physical abuse, emotional abuse, physical neglect, sexual abuse;
* Patient having signed an informed consent form to participate in the study.

Exclusion Criteria:

* Patient with a contraindication to magnetic resonance imaging or intermittent Theta Burst Stimulation (presence of a metallic body, pacemaker, implantable defibrillator or other implantable metallic device, epilepsy, stroke or recent head trauma);
* Patient who is not French-speaking or cannot read and write;
* Patient under guardianship;
* Patient in forced care (psychiatric care upon decision of the State representative and psychiatric care at the request of a third party);
* Pregnant woman or likely to be pregnant (of childbearing age) without effective contraception or breastfeeding;
* Patient participating in another clinical trial, or during a period of exclusion from another clinical trial;
* Patient who is not a beneficiary of a social security system.
* Patient who, according to the assessment of the investigator, risks not being compliant or diligent in the study procedures.

Primary outcomes:
measure: average of the Scale for assessment of negative symptoms/scale for assessment of positive symptoms scale scores
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Clinique Rech
Study officials:
References: